AKCEA-ANGPTL3-LRx

DRUG3 trials

Sponsors

Akcea Therapeutics

Conditions

Familial Chylomicronemia SyndromeFamilial Partial LipodystrophyHomozygous Familial HypercholesterolemiaHyperlipoproteinemia Type 1Lipoprotein Lipase Deficiency

Phase 2

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

CompletedNCT03360747

Akcea TherapeuticsFamilial Chylomicronemia Syndrome, Hyperlipoproteinemia Type 1, Lipoprotein Lipase Deficiency

Start: 2017-12-21End: 2018-09-04Updated: 2021-01-07

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

WithdrawnNCT03455777

Akcea TherapeuticsHomozygous Familial Hypercholesterolemia

Start: 2018-04-12End: 2018-12-31Updated: 2018-12-03

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

CompletedNCT03514420

Akcea TherapeuticsFamilial Partial Lipodystrophy

Start: 2018-06-15End: 2019-08-21Updated: 2021-02-16